Counselors in E Longmeadow, MA Accepting Medicare
2 Counselors found. Showing 1 - 2
 Linda Krasnow Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 200 N Main St, E Longmeadow, MA 01028 Phone: 413-530-1601 |
Ms. Rosemary Castonguay, MED Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 6 Lori Ln, E Longmeadow, MA 01028 Phone: 413-204-4675 |
News Archive
Researchers show possibility to restore insulin cell function in type 2 diabetes
By blocking a protein, VDAC1, in the insulin-producing beta cells, it is possible to restore their normal function in case of type 2 diabetes. In preclinical experiments, the researchers behind a new study have also shown that it is possible to prevent the development of the disease.
Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC
Microbix Biosystems Inc. today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).
Scientists discover protective role of retinoic acid against intestinal inflammation
Scientists at Trinity College Dublin have made novel discoveries around the protective influence of Vitamin A against the damaging immune responses that lead to inflammatory bowel disease.
AMRI initiates enrollment for Phase I study of ALB-127158 for obesity
AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.
› Verified 8 days ago